Effects of chronic risperidone treatment on the striatal protein profiles in rats

Brain Research

Volumn 1113, Issue 1, 2006, Pages 24-32

  O'Brien, Elizabeth ^a,b   Dedova, Irina ^a,b   Duffy, Liesl ^b,c   Cordwell, Stuart ^a   Karl, Tim ^b,c   Matsumoto, Izuru ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Neuroscience Institute of Schizophrenia and Allied Disorders   (Australia)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Antipsychotic drug; Extrapyramidal symptom; Proteomic; Risperidone; Sprague Dawley rat; Striatum

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; PROTEIN; RISPERIDONE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALEPSY; CELL CYCLE; COMPUTER PROGRAM; CONTROLLED STUDY; CORPUS STRIATUM; DNA BINDING; DOPAMINERGIC SYSTEM; EXTRAPYRAMIDAL SYMPTOM; MALE; MASTICATION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLIC DISORDER; METABOLISM; NONHUMAN; NUCLEOTIDE SEQUENCE; OSMOTIC MINIPUMP; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN TRANSPORT; RAT; STATISTICAL SIGNIFICANCE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DIAGNOSTIC IMAGING; DRUG ADMINISTRATION SCHEDULE; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; MALE; MASS SPECTROMETRY; PROTEINS; PROTEOMICS; RATS; RATS, SPRAGUE-DAWLEY; RISPERIDONE;

EID: 33748688816     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.07.009     Document Type: Article

References (53)

1. Aghajanian G.K., and Bunney B.S. Dopamine "autoreceptors": pharmacological characterization by microiontophoretic single cell recording studies. Naunyn-Schmiedeberg's Arch. Pharmacol. 297 (1977) 1-7
2. Alexander-Kaufman K., James G., Sheedy D., Harper C., and Matsumoto I. Differential protein expression in the prefrontal white matter of human alcoholics: a proteomics study. Mol. Psychiatry 11 (2006) 56-65
3. Andreassen O.A., Ferrante R.J., Beal M.F., and Jorgensen H.A. Oral dyskinesias and striatal lesions in rats after long-term co-treatment with haloperidol and 3-nitropropionic acid. Neuroscience 87 (1998) 639-648
4. Arnt J. Pharmacological differentiation of classical and novel antipsychotics. Int. Clin. Psychopharmacol. 13 Suppl. 3 (1998) S7-S14
5. Beal M.F. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann. N. Y. Acad. Sci. 991 (2003) 120-131
6. Berg, J.M., Tymoczko, J.L., Stryer, L., Biochemistry, 5th edn., W.H. Freeman, New York, 2002, xxxviii, 974, 3, 7, 28, 34 pp.
7. Boyd-Kimball D., Castegna A., Sultana R., Poon H.F., Petroze R., Lynn B.C., Klein J.B., and Butterfield D.A. Proteomic identification of proteins oxidized by Abeta(1-42) in synaptosomes: implications for Alzheimer's disease. Brain Res. 1044 (2005) 206-215
8. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
9. Bunney B.S., Walters J.R., Roth R.H., and Aghajanian G.K. Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity. J. Pharmacol. Exp. Ther. 185 (1973) 560-571
10. Burgoyne R.D., O'Callaghan D.W., Hasdemir B., Haynes L.P., and Tepikin A.V. Neuronal Ca2+-sensor proteins: multitalented regulators of neuronal function. Trends Neurosci. 27 (2004) 203-209
11. Butterfield D.A., Boyd-Kimball D., and Castegna A. Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration. J. Neurochem. 86 (2003) 1313-1327
12. Cavelier L., Jazin E.E., Eriksson I., Prince J., Bave U., Oreland L., and Gyllensten U. Decreased cytochrome-c oxidase activity and lack of age-related accumulation of mitochondrial DNA deletions in the brains of schizophrenics. Genomics 29 (1995) 217-224
13. Chandra S., Gallardo G., Fernandez-Chacon R., Schluter O.M., and Sudhof T.C. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123 (2005) 383-396
14. Choo Y.S., Mao Z., Johnson G.V., and Lesort M. Increased glutathione levels in cortical and striatal mitochondria of the R6/2 Huntington's disease mouse model. Neurosci. Lett. 386 (2005) 63-68
15. Chue P., and Cheung R. The impact of weight gain associated with atypical antipsychotic use in schizophrenia. Acta Neuropsychiatrica 16 (2004) 113-123
16. Feher L.Z., Kalman J., Puskas L.G., Gyulveszi G., Kitajka K., Penke B., Palotas M., Samarova E.I., Molnar J., Zvara A., Matin K., Bodi N., Hugyecz M., Pakaski M., Bjelik A., Juhasz A., Bogats G., Janka Z., and Palotas A. Impact of haloperidol and risperidone on gene expression profile in the rat cortex. Neurochem. Int. 47 (2005) 271-280
17. Glick I.D., and Berg P.H. Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. Int. Clin. Psychopharmacol. 17 (2002) 65-68
18. Heffner T.G., Hartman J.A., and Seiden L.S. A rapid method for the regional dissection of the rat brain. Pharmacol. Biochem. Behav. 13 (1980) 453-456
19. Hemmer W., and Wallimann T. Functional aspects of creatine kinase in brain. Dev. Neurosci. 15 (1993) 249-260
20. Hoffman D.C., and Donovan H. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology 120 (1995) 128-133
21. Howitt S.M., Gibson F., and Cox G.B. The proton pore of the F0F1-ATPase of Escherichia coli: Ser-206 is not required for proton translocation. Biochim. Biophys. Acta 936 (1988) 74-80
22. Kaldis P., Hemmer W., Zanolla E., Holtzman D., and Wallimann T. 'Hot spots' of creatine kinase localization in brain: cerebellum, hippocampus and choroid plexus. Dev. Neurosci. 18 (1996) 542-554
23. Kapur S. A new framework for investigating antipsychotic action in humans: lessons from PET imaging. Mol. Psychiatry 3 (1998) 135-140
24. Kapur S., VanderSpek S.C., Brownlee B.A., and Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J. Pharmacol. Exp. Ther. 305 (2003) 625-631
25. Kim T.D., Paik S.R., Yang C.H., and Kim J. Structural changes in alpha-synuclein affect its chaperone-like activity in vitro. Protein Sci. 9 (2000) 2489-2496
26. Knable M.B., Heinz A., Raedler T., and Weinberger D.R. Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. Psychiatry Res. 75 (1997) 91-101
27. Kobayashi M., Takamatsu K., Saitoh S., Miura M., and Noguchi T. Molecular cloning of hippocalcin, a novel calcium-binding protein of the recoverin family exclusively expressed in hippocampus. Biochem. Biophys. Res. Commun. 189 (1992) 511-517
28. Leysen J.E., Gommeren W., Eens A., de Chaffoy de Courcelles D., Stoof J.C., and Janssen P.A. Biochemical profile of risperidone, a new antipsychotic. J. Pharmacol. Exp. Ther. 247 (1988) 661-670
29. Leysen J.E., Janssen P.M., Gommeren W., Wynants J., Pauwels P.J., and Janssen P.A. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol. Pharmacol. 41 (1992) 494-508
30. Lubec G., Nonaka M., Krapfenbauer K., Gratzer M., Cairns N., and Fountoulakis M. Expression of the dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimer's disease brain is downregulated at the mRNA and dysregulated at the protein level. J. Neural Transm., Suppl. 57 (1999) 161-177
31. Manczak M., Park B.S., Jung Y., and Reddy P.H. Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage. Neuromol. Med. 5 (2004) 147-162
32. Marchese G., Bartholini F., Casu M.A., Ruiu S., Casti P., Congeddu E., Tambaro S., and Pani L. Haloperidol versus risperidone on rat "early onset" vacuous chewing. Behav. Brain Res. 149 (2004) 9-16
33. Marder S.R., Glynn S.M., Wirshing W.C., Wirshing D.A., Ross D., Widmark C., Mintz J., Liberman R.P., and Blair K.E. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am. J. Psychiatry 160 (2003) 1405-1412
34. Maurer I., and Moller H.J. Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Mol. Cell. Biochem. 174 (1997) 255-259
35. Maurer I., Zierz S., and Moller H. Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. Schizophr. Res. 48 (2001) 125-136
36. Mitchell I.J., Cooper A.C., Griffiths M.R., and Cooper A.J. Acute administration of haloperidol induces apoptosis of neurones in the striatum and substantia nigra in the rat. Neuroscience 109 (2002) 89-99
37. O'Callaghan D.W., Haynes L.P., and Burgoyne R.D. High-affinity interaction of the N-terminal myristoylation motif of the neuronal calcium sensor protein hippocalcin with phosphatidylinositol 4,5-bisphosphate. Biochem. J. 391 (2005) 231-238
38. Prabakaran S., Swatton J.E., Ryan M.M., Huffaker S.J., Huang J.T., Griffin J.L., Wayland M., Freeman T., Dudbridge F., Lilley K.S., Karp N.A., Hester S., Tkachev D., Mimmack M.L., Yolken R.H., Webster M.J., Torrey E.F., and Bahn S. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry 9 (2004) 684-697 643
39. Prince J.A., Yassin M.S., and Oreland L. Normalization of cytochrome-c oxidase activity in the rat brain by neuroleptics after chronic treatment with PCP or methamphetamine. Neuropharmacology 36 (1997) 1665-1678
40. Scheepers F.E., de Wied C.C., Hulshoff Pol H.E., van de Flier W., van der Linden J.A., and Kahn R.S. The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics. Neuropsychopharmacology 24 (2001) 47-54
41. Schwarcz G. A rational ordering of the actions of antipsychotic drugs. J. Fam. Pract. 14 (1982) 263-267
42. Shen W., Willis D., Zhang Y., Schlattner U., Wallimann T., and Molloy G.R. Expression of creatine kinase isoenzyme genes during postnatal development of rat brain cerebellum: evidence for transcriptional regulation. Biochem. J. 367 (2002) 369-380
43. Shimizu T., Matsuoka Y., and Shirasawa T. Biological significance of isoaspartate and its repair system. Biol. Pharm. Bull. 28 (2005) 1590-1596
44. Sian J., Dexter D.T., Lees A.J., Daniel S., Agid Y., Javoy-Agid F., Jenner P., and Marsden C.D. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36 (1994) 348-355
45. Souza J.M., Giasson B.I., Lee V.M., and Ischiropoulos H. Chaperone-like activity of synucleins. FEBS Lett. 474 (2000) 116-119
46. Tejedor-Real P., Faucon Biguet N., Dumas S., and Mallet J. Tyrosine hydroxylase mRNA and protein are down-regulated by chronic clozapine in both the mesocorticolimbic and the nigrostriatal systems. J. Neurosci. Res. 72 (2003) 105-115
47. Tsai G., Goff D.C., Chang R.W., Flood J., Baer L., and Coyle J.T. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am. J. Psychiatry 155 (1998) 1207-1213
48. Wadenberg M.L., Kapur S., Soliman A., Jones C., and Vaccarino F. Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology 150 (2000) 422-429
49. Wadenberg M.L., Soliman A., VanderSpek S.C., and Kapur S. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25 (2001) 633-641
50. Walton M., Sirimanne E., Reutelingsperger C., Williams C., Gluckman P., and Dragunow M. Annexin V labels apoptotic neurons following hypoxia-ischemia. NeuroReport 8 (1997) 3871-3875
51. Xu J., Kao S.Y., Lee F.J., Song W., Jin L.W., and Yankner B.A. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8 (2002) 600-606
52. Yoshimura R., Ueda N., and Nakamura J. Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study. Neuropsychobiology 44 (2001) 129-133
53. Zheng J., and Ramirez V.D. Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals. Br. J. Pharmacol. 130 (2000) 1115-1123